Drug intelligence / Profile preview

nefopam + ketoprofen + paracetamol

Development stage: Unknown
Lead developer: Rivo
Modality: Small Molecules
Administration: Intravenous

Overview

A multimodal analgesic combination used primarily for postoperative pain management. This combination leverages the different mechanisms of action of each component to provide enhanced pain relief while reducing opioid requirements. Clinical studies have shown that this combination significantly reduces morphine consumption and pain scores after surgery compared to dual combinations or single agents.

Other names: nefopam + ketoprofen + acetaminophen

Targets

SERT (Sodium-dependent serotonin transporter)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on nefopam + ketoprofen + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nefopam + ketoprofen + paracetamol.

Explore the full profile